Medpace Holdings Inc
MEDP561.650USD
-7.200-1.27%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
15.78BMarket Cap
38.30P/E TTM
More Details of Medpace Holdings Inc Company
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Medpace Holdings Inc Info
Ticker SymbolMEDP
Company nameMedpace Holdings Inc
IPO dateAug 11, 2016
CEOTroendle (August J)
Number of employees5900
Security typeOrdinary Share
Fiscal year-endAug 11
Address5375 Medpace Way
CityCINCINNATI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code45227-1543
Phone15135799911
Websitehttps://investor.medpace.com/
Ticker SymbolMEDP
IPO dateAug 11, 2016
CEOTroendle (August J)
Company Executives of Medpace Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Dr. August J. Troendle, M.D.
Dr. August J. Troendle, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
646.18K
-4.37%
Mr. Brian T. Carley
Mr. Brian T. Carley
Independent Director
Independent Director
26.28K
+0.24%
Mr. Jesse J. Geiger, CPA
Mr. Jesse J. Geiger, CPA
President
President
15.00K
-58.91%
Mr. Stephen P. Ewald, J.D.
Mr. Stephen P. Ewald, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
13.34K
+29.01%
Mr. Robert O. Kraft
Mr. Robert O. Kraft
Independent Director
Independent Director
890.00
--
Dr. Dani S. Zander
Dr. Dani S. Zander
Independent Director
Independent Director
--
--
Mr. Cornelius P. Mccarthy, III
Mr. Cornelius P. Mccarthy, III
Independent Director
Independent Director
--
--
Mr. Kevin M. Brady
Mr. Kevin M. Brady
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Fred B. Davenport, Jr.
Mr. Fred B. Davenport, Jr.
Lead Independent Director
Lead Independent Director
--
--
Ms. Susan E. Burwig
Ms. Susan E. Burwig
Executive Vice President - Operations
Executive Vice President - Operations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. August J. Troendle, M.D.
Dr. August J. Troendle, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
646.18K
-4.37%
Mr. Brian T. Carley
Mr. Brian T. Carley
Independent Director
Independent Director
26.28K
+0.24%
Mr. Jesse J. Geiger, CPA
Mr. Jesse J. Geiger, CPA
President
President
15.00K
-58.91%
Mr. Stephen P. Ewald, J.D.
Mr. Stephen P. Ewald, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
13.34K
+29.01%
Mr. Robert O. Kraft
Mr. Robert O. Kraft
Independent Director
Independent Director
890.00
--
Dr. Dani S. Zander
Dr. Dani S. Zander
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
By BusinessUSD
Name
Revenue
Proportion
Oncology
188.56M
31.25%
Metabolic
147.87M
24.51%
Other
118.06M
19.57%
Central Nervous System
61.13M
10.13%
Cardiology
58.58M
9.71%
AVAI
29.11M
4.82%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Oncology
188.56M
31.25%
Metabolic
147.87M
24.51%
Other
118.06M
19.57%
Central Nervous System
61.13M
10.13%
Cardiology
58.58M
9.71%
AVAI
29.11M
4.82%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Medpace Investors, L.L.C.
16.80%
The Vanguard Group, Inc.
8.08%
BlackRock Institutional Trust Company, N.A.
7.47%
AQR Capital Management, LLC
3.64%
Wasatch Global Investors Inc
3.29%
Other
60.71%
Shareholders
Shareholders
Proportion
Medpace Investors, L.L.C.
16.80%
The Vanguard Group, Inc.
8.08%
BlackRock Institutional Trust Company, N.A.
7.47%
AQR Capital Management, LLC
3.64%
Wasatch Global Investors Inc
3.29%
Other
60.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor
47.07%
Investment Advisor/Hedge Fund
26.12%
Corporation
16.80%
Hedge Fund
6.47%
Research Firm
3.77%
Individual Investor
2.74%
Pension Fund
2.01%
Family Office
1.65%
Family Office
1.65%
Institutional Shareholding
Updated: 23 hours ago
Updated: 23 hours ago
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1262
24.54M
87.12%
-4.90M
2025Q3
1221
26.75M
94.97%
-1.63M
2025Q2
1184
32.22M
114.46%
-1.64M
2025Q1
1189
32.19M
111.84%
-1.65M
2024Q4
1154
31.87M
104.30%
-1.77M
2024Q3
1089
31.75M
102.26%
-1.23M
2024Q2
1042
31.55M
102.01%
-1.83M
2024Q1
995
31.67M
102.27%
-1.17M
2023Q4
938
31.80M
103.67%
-407.87K
2023Q3
885
31.39M
102.53%
-1.87M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Medpace Investors, L.L.C.
4.73M
16.8%
--
--
Nov 28, 2025
The Vanguard Group, Inc.
2.28M
8.08%
-107.66K
-4.51%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.10M
7.47%
-112.24K
-5.06%
Sep 30, 2025
AQR Capital Management, LLC
1.03M
3.64%
+404.23K
+65.07%
Sep 30, 2025
Wasatch Global Investors Inc
925.96K
3.29%
-19.85K
-2.10%
Sep 30, 2025
State Street Investment Management (US)
673.14K
2.39%
-33.64K
-4.76%
Sep 30, 2025
Mawer Investment Management Ltd.
646.77K
2.3%
-170.66K
-20.88%
Sep 30, 2025
Troendle (August J)
646.18K
2.29%
-29.54K
-4.37%
Dec 03, 2025
Geode Capital Management, L.L.C.
642.67K
2.28%
+4.75K
+0.74%
Sep 30, 2025
D. E. Shaw & Co., L.P.
600.14K
2.13%
+256.58K
+74.68%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Franklin Genomic Advancements ETF
5.91%
Invesco Dorsey Wright Healthcare Momentum ETF
5.53%
Argent Mid Cap ETF
5.35%
Aztlan Global Stock Selection DM SMID ETF
4.2%
Invesco S&P MidCap Quality ETF
4.17%
Invesco S&P MidCap 400 GARP ETF
3.39%
Janus Henderson Small/Mid Cap Growth Alpha ETF
3.14%
ERShares Entrepreneurs ETF
3.08%
Congress SMid Growth ETF
3%
Pacer US Large Cap Cash Cows Growth Leaders ETF
2.49%
View more
Franklin Genomic Advancements ETF
Proportion5.91%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion5.53%
Argent Mid Cap ETF
Proportion5.35%
Aztlan Global Stock Selection DM SMID ETF
Proportion4.2%
Invesco S&P MidCap Quality ETF
Proportion4.17%
Invesco S&P MidCap 400 GARP ETF
Proportion3.39%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion3.14%
ERShares Entrepreneurs ETF
Proportion3.08%
Congress SMid Growth ETF
Proportion3%
Pacer US Large Cap Cash Cows Growth Leaders ETF
Proportion2.49%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Medpace Holdings Inc?
The top five shareholders of Medpace Holdings Inc are:
Medpace Investors, L.L.C. holds 4.73M shares, accounting for 16.80% of the total shares.
The Vanguard Group, Inc. holds 2.28M shares, accounting for 8.08% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.10M shares, accounting for 7.47% of the total shares.
AQR Capital Management, LLC holds 1.03M shares, accounting for 3.64% of the total shares.
Wasatch Global Investors Inc holds 925.96K shares, accounting for 3.29% of the total shares.
Medpace Investors, L.L.C. holds 4.73M shares, accounting for 16.80% of the total shares.
The Vanguard Group, Inc. holds 2.28M shares, accounting for 8.08% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.10M shares, accounting for 7.47% of the total shares.
AQR Capital Management, LLC holds 1.03M shares, accounting for 3.64% of the total shares.
Wasatch Global Investors Inc holds 925.96K shares, accounting for 3.29% of the total shares.
What are the top three shareholder types of Medpace Holdings Inc?
The top three shareholder types of Medpace Holdings Inc are:
Medpace Investors, L.L.C.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Medpace Investors, L.L.C.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Medpace Holdings Inc (MEDP)?
As of 2025Q4, 1262 institutions hold shares of Medpace Holdings Inc, with a combined market value of approximately 24.54M, accounting for 87.12% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -7.85%.
What is the biggest source of revenue for Medpace Holdings Inc?
In FY2025Q2, the Oncology business generated the highest revenue for Medpace Holdings Inc, amounting to 188.56M and accounting for 31.25% of total revenue.
